Clinical Research Directory

Inclusion Criteria (mod-high/risk trial participants): * Adults (≥ 18years) with scheduled Chemotherapy. Specifically, patients who meet the following diagnosis and treatment window requirements: * Myeloma- Autologous Stem Cell Transplantation (ASCT) before high-dose myeloablative CT. * Haematological cancers suitable for Allografts Stem Cell Transplant (SCT) before CT * Moderate / High Oral Health Risk Assessment - any one of the following: * Clinical evidence of caries (2+ teeth) * Clinical evidence on soft and hard tissue examination of infection, sinus, swelling or tenderness * BPE code 3-4 in any remaining sextant * BPE code 1-2 with \>30% BOP * The patient is fully informed, has received PIS (patient information sheet) and considered during a 'cooling-off' period, is competent to consent, and is able to comply with minimum attendance requirements Exclusion Criteria: * Have a history of head and neck radiotherapy * Have been treated with Denusomab, Bevacizumab, Sunitinib or Aflibercept within 9 months of the MDT date. * Insufficient teeth \[defined as \<2\] * Are incapable of providing informed written consent * Are unable to comply with minimum attendance requirements